15 December 2020 : Clinical Research
Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma
Yu Qian1ABCDEF, Jing-Wen Wang1BC, Yu Fang1BCD, Xiao-Dong Yuan1B, Yu-Chen Fan12ADF, Shuai Gao12CDFG, Kai Wang12ADEG*DOI: 10.12659/MSM.927444
Med Sci Monit 2020; 26:e927444
Figure 4 Receiver operating characteristic curves (ROC) of AFP, CCND2 promoter methylation, and combined measurement for distinguishing HCC from LC and CHB in both PBMCs and plasma. (A) The area under the ROC curves (AUC) of combined measurement in PBMCs was significantly higher than that of AFP levels for discriminating HCC from LC patients (AUC 0.698 vs. 0.540, P<0.001). (B) The AUC of combined measurement in plasma was significantly higher than that of AFP levels for discriminating HCC from LC patients (AUC 0.694 vs. 0.540, P<0.001). (C) The AUC of combined measurement in PBMCs was significantly higher than that of AFP levels for discriminating HCC from CHB patients (AUC 0.724 vs. 0.571, P<0.001). (D) The AUC of combined measurement in plasma was significantly higher than that of AFP levels for discriminating HCC from CHB patients (AUC 0.720 vs. 0.571, P<0.001).